Preclinical data released for potential DME treatment

Article

NCX 434, a new drug candidate form NicOx, is reported to improve oxygen saturation in the eye and preclinical data was recently presented at the Ocular Diseases & Drug Discovery Conference

NCX 434, a new drug candidate form NicOx, is reported to improve oxygen saturation in the eye and preclinical data was recently presented at the Ocular Diseases & Drug Discovery Conference in the United States in anticipation that the results may assist DME future treatment.

In its press statement NicOx said that the effects of intravitreal injections of NCX 434 or triamcinolone, a reference steroid, on oxygen saturation in the optic nerve head (ONH) and overlaying arteries and veins were assessed in preclinical models. NCX 434, in contrast to triamcinolone, enhanced oxygen saturation (p

NCX 434 is believed to operate through a dual mechanism of action, having both vasoactive and anti-inflammatory activities. In this study, there was no significant difference in IOP with either compound. NCX 434 has been shown to elicit sustained efficacy in a VEGF-induced leakage model without causing an increase in IOP (unpublished results).

Bahram Khoobehi, Ph.D., Professor of Ophthalmology at the LSU Eye Center, Louisiana State University Health Sciences Center, New Orleans, commented: “ The preclinical results obtained with NCX 434 in collaboration with NicOx show the potential for a compelling differentiated profile. Tissue oxygenation is often defective in DME patients and is not addressed with current drug therapy. I am looking forward to seeing further data on this drug candidate.”

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.